Merck's RSV antibody drug Enflonsia has received FDA approval for infants under 12 months, entering a market dominated by Sanofi and AstraZeneca's Beyfortus. This approval coincides with the Health and Human Services Secretary Robert F. Kennedy Jr.'s unprecedented removal of all members from the CDC's Advisory Committee on Immunization Practices (ACIP), which advises on vaccine usage, creating uncertainty around upcoming vaccine recommendations. The overhaul has disrupted the continuity of vaccine policy guidance during a pivotal moment for pediatric RSV prophylaxis.